1. Home
  2. Funding
  3. Funding Opportunities
  4. Substance Abuse Service Expansion Technical Assistance

Substance Abuse Service Expansion Technical Assistance

About the Substance Abuse Service Expansion

The Fiscal Year (FY) 2016 Affordable Care Act Substance Abuse Service Expansion Supplement supports the improvement and expansion of substance abuse services provided by existing Health Center Program award recipients (those currently funded under section 330 of the Public Health Service Act), with a focus on medication-assisted treatment (MAT) for opioid use disorders. HRSA awarded $94 million to 271 health centers in FY 2016.

Quarterly Progress Reports

Health centers will submit quarterly updates on their Substance Abuse Service Expansion activities by providing information on each of the following:

  • Number of physicians who obtained a Drug Addiction Treatment Act of 2000 (DATA) waiver
  • Number of patients who received MAT
  • Issues and barriers
  • Key strategies and lessons learned

SA QPR Resources

Annual Reports

The following Uniform Data System metrics will be tracked by HRSA to measure progress.

  • Number of FTE substance abuse services providers
  • Number of patients receiving substance abuse services
  • Number of visits for substance abuse services
  • Number of patients receiving SBIRT services

Project Requirements

Required goals:

  • Establish or enhance an integrated primary care/behavioral health model.
  • Increase the number of patients screened for substance use disorders and connected to treatment via Screening, Brief Intervention, and Referral to Treatment (SBIRT) and other evidence-based practices.
  • Increase the number of patients with access to MAT for opioid use and other substance use disorders treatment by:
    • Adding at least 1.0 full time equivalent (FTE) substance abuse services provider(s) directly and/or through contract(s) within 120 days of award; and
    • Adding new or enhancing existing substance abuse services directly and/or through contract(s) within 120 days of award.
  • Coordinate services necessary for patients to achieve and sustain recovery.
  • Provide training and educational resources, including updated prescriber guidelines, to assist health professionals in making informed prescribing decisions and address the over-prescribing of opioids.

Optional goals:

  • Increase education, screening, care coordination, risk reduction interventions (such as comprehensive treatment for injectable drug use), and/or counseling for HIV/AIDS, hepatitis, and other diseases associated with opioid use disorders.
  • Enhance clinical workflows to improve substance abuse services.
  • Enhance the use of health information technologies to improve the effectiveness of substance abuse services and increase patient engagement.
  • Educate patients and/or community members on opioid use disorders, including the use of opioid antagonists in preventing opioid overdose.

Use of MAT must be consistent with federal statutes and regulations.

FDA-approved MAT Pharmacotherapy for Opioid Use Disorder 340B Pricing Available Generic Available at 340B Price
vivitrol (naltrexone extended-release injectable suspension) Yes No
methadone Yes Yes
buprenorphine Yes Yes
Date Last Reviewed: